Scarica l'app Stockscreener
29.94
1.87%
-0.57
Dopo l'orario di chiusura:
29.99
0.05
+0.17%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VKTX Giù?
Forum
Previsione
Precedente Chiudi:
$30.51
Aprire:
$30.85
Volume 24 ore:
6.34M
Relative Volume:
1.68
Capitalizzazione di mercato:
$3.73B
Reddito:
-
Utile/perdita netta:
$-472.34M
Rapporto P/E:
-7.2216
EPS:
-4.1459
Flusso di cassa netto:
$-340.33M
1 W Prestazione:
-15.80%
1M Prestazione:
-10.63%
6M Prestazione:
-13.97%
1 anno Prestazione:
+7.39%
Intervallo 1D:
$29.90
$31.09
Intervallo di 1 settimana:
$29.90
$35.19
Portata 52W:
$25.77
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
Nome
Viking Therapeutics Inc
Settore
Industria
Telefono
858-704-4660
Indirizzo
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
29.94 | 4.43B | 0 | -472.34M | -340.33M | -4.1459 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-26 | Iniziato | Wolfe Research | Peer Perform |
| 2025-10-29 | Iniziato | Canaccord Genuity | Buy |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Iniziato | Goldman | Neutral |
| 2025-02-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-07 | Iniziato | Citigroup | Neutral |
| 2024-12-02 | Iniziato | Piper Sandler | Overweight |
| 2024-11-22 | Iniziato | B. Riley Securities | Buy |
| 2024-11-04 | Reiterato | H.C. Wainwright | Buy |
| 2024-09-11 | Iniziato | JP Morgan | Overweight |
| 2024-06-27 | Iniziato | Morgan Stanley | Overweight |
| 2024-05-16 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | Reiterato | Oppenheimer | Outperform |
| 2024-03-07 | Iniziato | Jefferies | Buy |
| 2024-02-28 | Reiterato | Oppenheimer | Outperform |
| 2023-05-31 | Ripresa | ROTH MKM | Buy |
| 2023-03-28 | Reiterato | Maxim Group | Buy |
| 2023-03-17 | Iniziato | Stifel | Buy |
| 2021-07-29 | Ripresa | BTIG Research | Buy |
| 2021-05-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | Iniziato | BMO Capital Markets | Outperform |
| 2020-05-05 | Iniziato | Chardan Capital Markets | Buy |
| 2020-05-01 | Iniziato | BTIG Research | Buy |
| 2019-07-16 | Iniziato | Oppenheimer | Outperform |
| 2019-06-25 | Iniziato | Stifel | Buy |
| 2019-03-29 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | Reiterato | Maxim Group | Buy |
| 2019-02-22 | Iniziato | SVB Leerink | Mkt Perform |
| 2018-12-12 | Iniziato | B. Riley FBR | Buy |
| 2018-11-19 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | Reiterato | H.C. Wainwright | Buy |
| 2018-09-18 | Reiterato | Maxim Group | Buy |
| 2018-09-18 | Reiterato | Raymond James | Outperform |
| 2018-07-20 | Iniziato | SunTrust | Buy |
| 2018-06-28 | Iniziato | Raymond James | Outperform |
| 2018-06-01 | Reiterato | Laidlaw | Buy |
| 2018-05-31 | Reiterato | Maxim Group | Buy |
| 2018-03-26 | Ripresa | H.C. Wainwright | Buy |
| 2017-11-28 | Reiterato | Maxim Group | Buy |
| 2017-11-21 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Viking Therapeutics Inc Borsa (VKTX) Ultime notizie
Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock. - The Motley Fool
Viking Therapeutics, Inc. (VKTX) Rises As Market Takes a Dip: Key Facts - Yahoo Finance Singapore
3 Emerging Biotech Stocks With Significant Upside Potential - Yahoo Finance
Free cash flow of Viking Therapeutics, Inc. – HAN:1VT - TradingView
Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why. - theglobeandmail.com
Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why. - The Motley Fool
3 Non-AI Growth Stocks That Have Massive Upside - Yahoo Finance
VKTX Stock Logs 3-Day Losing Streak As $548M Raise Closes — Retail Calls Dip An ‘Easy Buy’ Amid Buyout Talks - TradingView
Viking Therapeutics (VKTX) Raises $575M in Upsized Stock and Con - GuruFocus
Viking Completes $575 Million Financing Round - Intellectia AI
Form 8K Viking Therapeutics Inc For: 28 September By Investing.com - Investing.com Nigeria
Viking Therapeutics Raises $547.8 Million via Equity Sale and 2.00% Convertible Notes - TradingView
Viking Therapeutics nets ~$550M in proceeds from latest offering - TradingView
Viking Therapeutics raises $575 million in dual offering - Investing.com
Viking Therapeutics raises $575 million in dual offering By Investing.com - Investing.com Australia
Viking Therapeutics (VKTX) Closes Upsized Stock and 2.00% Convertible Notes Offerings, ~$575M Gross - TradingView
Viking Therapeutics, Inc. Bonds — Corporate Bond Rates - TradingView
Viking Therapeutics (VKTX): VK2735 Data Look Strong, but Cash Burn Still Matters - AlphaStreet
Viking Therapeutics posts strong obesity drug t... - Pluang
Viking Therapeutics Draws Investor Investigations - stl.news
Viking Therapeutics Adds Weight Loss Maintenance As Potential New Growth Driver (VKTX) - Seeking Alpha
Investigation launched into Viking Therapeutics' officers for possible self-dealing harming shareholders - Pluang
Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm - Morningstar
Could This Mid-Cap GLP-1 Stock Be a Better Buy Than Eli Lilly? - The Motley Fool
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It? - Yahoo Finance
Viking Therapeutics (VKTX) Delivers Great VK2735 Results: Here's a Word of Caution - Yahoo Finance
VKTX Stock Eyes Blockbuster Week Despite Share Offering — Retail Traders See A Stronger Hand In Buyout Talks - Stocktwits
3 Numbers From Viking Therapeutics' Weight-Loss Drug Trial That Have Wall Street Buzzing - Yahoo Finance
VKTX Stock Rallies After Hours On Optimism Around Company’s Obesity Pipeline - Stocktwits
VKTX Stock Reverses Weight-Loss Drug Gains As Viking Unveils $500M Discounted Financing - Stocktwits
VKTX Stock On Track To Beat LLY, NVO This Month After Obesity Drug Data — Can Viking Win Over Wegovy And Zepbound Users? - Stocktwits
VKTX Stock Outpaces LLY, ALT Ahead Of Earnings – Retail Eyes Breakout Ahead - Stocktwits
VKTX Stock Lags GLP-1 Peers In July — But Viking CEO Says Its Obesity Drug Could Offer What Rivals Can’t - Stocktwits
Viking Therapeutics Stock (VKTX) Opinions on Positive Obesity Drug Data Release - Quiver Quantitative
What Viking Therapeutics Stock Means For Shareholders After Obesity Drug Data And $500 Million Raise - simplywall.st
VKTX 10-Q FilingsViking Therapeutics, Inc SEC 10-Q - Stock Titan
Viking Therapeutics Adds Weight Loss Maintenance As Potential New Growth Driver (NASDAQ:VKTX) - Seeking Alpha
Is Viking Therapeutics (VKTX) Getting Too Rich After VK2735 Data? - Yahoo Finance
Biotech Stocks To ResearchSeptember 25th - MarketBeat
VKTX Form 4 FilingsViking Therapeutics, Inc SEC Form 4 - Stock Titan
Is Viking Therapeutics, Inc. (VKTX) the Healthcare Stocks Stock Everyone's About to Talk About? - Kalkine Media
Form 424B5 Viking Therapeutics Inc For: 25 September - Investing.com India
Latham Advises on Viking Therapeutics’ Upsized US$500 Million Offering of Common Stock and Convertible Senior Notes - Legal Desire
Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy? - The Motley Fool
Form 424B5 Viking Therapeutics Inc For: 25 September By Investing.com - Investing.com Canada
VKTX Stock Steady After-Hours On Positive Obesity Drug Pipeline Progress - Stocktwits
Viking Therapeutics (VKTX) Stock Looks Fully Priced Despite Its Huge Five Year Run - simplywall.st
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
Viking Therapeutics Plunges After Upsized $500 Million Financing Prices at 16% Discount - finance.biggo.com
Viking Therapeutics Share Drop After Upsized Stock, Notes Offerings - moomoo.com
One investor reportedly took a third of Viking’s share sale - Yahoo Finance Australia
Viking Therapeutics Inc Azioni (VKTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Viking Therapeutics Inc Azioni (VKTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ZANTE GREG | Chief Financial Officer |
Jul 29 '26 |
Sale |
33.47 |
21,217 |
710,141 |
212,204 |
| Mancini Marianna | Chief Operating Officer |
Jul 29 '26 |
Sale |
33.47 |
18,217 |
609,636 |
422,760 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):